<?xml version="1.0" encoding="UTF-8"?>
<p id="Par34">Gene therapy uses adeno-associated virus vectors to deliver engineered DNA to human cells [
 <xref ref-type="bibr" rid="CR43">43</xref>, 
 <xref ref-type="bibr" rid="CR66">66</xref>]. For 
 <italic>GBA</italic>, preclinical studies in mice demonstrated that adeno-associated virus-mediated expression of glucocerebrosidase corrected the aberrant accumulation of the toxic lipid glucosylsphingosine and reduced the levels of ubiquitin, tau, and Î±-syn aggregates [
 <xref ref-type="bibr" rid="CR67">67</xref>]. Prevail Therapeutics, a new company launched in 2017, started a gene therapy clinical trial of PR001 in 16 
 <italic>GBA-</italic>PD patients in late 2019 (
 <ext-link ext-link-type="uri" xlink:href="https://ir.prevailtherapeutics.com/news-releases/news-release-details/prevail-therapeutics-provides-program-update-pr001-parkinsons-0" xmlns:xlink="http://www.w3.org/1999/xlink">https://ir.prevailtherapeutics.com/news-releases/news-release-details/prevail-therapeutics-provides-program-update-pr001-parkinsons-0)</ext-link>. The company will also test the compound in children with neuropathic Gaucher disease starting in the first half of 2020.
</p>
